0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Natalizumab Treatment in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy FREE

Christian Wolf, MD; Til Menge, MD; Max-Philipp Stenner, MSc; Gerd Meyer zu Hörste, MD; Andreas Saleh, MD; Hans-Peter Hartung, MD; Heinz Wiendl, MD; Bernd C. Kieseier, MD
[+] Author Affiliations

Author Affiliations: Departments of Neurology (Drs Wolf, Menge, Meyer zu Hörste, Hartung, and Kieseier) and Radiology (Dr Saleh), Heinrich-Heine University, Düsseldorf, Germany; and Department of Neurology, Julius-Maximilians University, Würzburg, Germany (Mr Stenner and Dr Wiendl).


Arch Neurol. 2010;67(7):881-883. doi:10.1001/archneurol.2010.143.
Text Size: A A A
Published online

ABSTRACT

Objective  To study clinical and paraclinical effects of natalizumab in a patient with chronic inflammatory demyelinating polyneuropathy (CIDP).

Design  Case report.

Setting  Department of Neurology, Heinrich-Heine University, Düsseldorf, Germany.

Patient  A patient with highly active CIDP who did not respond to standard therapies.

Intervention  Standard therapy then treatment with natalizumab (300 mg).

Main Outcome Measures  Clinical disability, magnetic resonance imaging, and saturation of the α4 integrin on T lymphocytes.

Results  T cells expressing the α4 integrin were found in the inflamed peripheral nerve. Natalizumab bound with high affinity to the α4 integrin on T lymphocytes in our patient. However, the patient's clinical condition deteriorated and as seen on magnetic resonance imaging without any measurable effect after treatment with this antibody.

Conclusions  Although experimental evidence suggests that natalizumab could theoretically be effective in immune-mediated disorders of the peripheral nervous system, our patient with CIDP did not benefit from this therapeutic approach. Natalizumab cannot be recommended in CIDP at present and should only be explored in controlled clinical trials.

Figures in this Article

Natalizumab is a humanized monoclonal antibody against the α4 integrin approved for treating relapsing forms of multiple sclerosis.1 Experimental evidence in an animal model suggests that targeting α4 integrins in the inflamed peripheral nervous system may translate into clinical efficacy.2,3 Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disease in which an aberrant immune response, often T cell driven, is mounted against a yet unknown target antigen within the peripheral nerve.4 A number of immunomodulatory and suppressive treatment strategies, though generally not approved by regulatory authorities, are currently used for treating CIDP. However, clinical efficacy of these therapeutic approaches varies in the clinical subtypes of this disease, requiring different strategies, including individualized regimens of drug administration.5 Theoretically, there is a good rationale that natalizumab should be clinically effective in CIDP as well, yet clinical experience has not been reported so far.

REPORT OF A CASE

We report on the case of a 61-year-old woman with CIDP diagnosed 28 months before presentation. Clinical and paraclinical evidence for a paraneoplastic disorder was not given; a monoclonal gammopathy was excluded. The patient failed to respond to established treatment strategies, including steroids, azathioprine (discontinued after 8 months because of loss of hair), intravenous immunoglobulins, mycophenolate mofetil, and cyclophosphamide (Figure 1). Plasma exchange (PE) was the only therapeutic approach that resulted in transient clinical improvement. After a course of 5 cycles of PE within 10 consecutive days, mild tetraparesis remained. However, within 3 weeks the patient's condition deteriorated dramatically clinically and paraclinically (Table 1 and Table 2). She became paraplegic and required a new course of PE; she recovered with the remaining sequelae just described. The patient was referred to our center to explore alternative treatment options.

Place holder to copy figure label and caption
Figure 1.

Past therapeutic regimens of a patient with chronic inflammatory demyelinating polyneuropathy. IVIg indicates high-dose intravenous immunoglobulin; MRI I, magnetic resonance imaging prior to PE; MRI II, after PE, prior to natalizumab; MRI III, 3 weeks after natalizumab treatment; PE, plasma exchange.

Graphic Jump Location
Table Graphic Jump LocationTable 1. Electrophysiological Assessments in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
Table Graphic Jump LocationTable 2.  Analysis of Cerebrospinal Fluid in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy

Given the need for PE at high frequency and the lack of established alternative treatment choices, we considered natalizumab to be a therapeutic option. After discussing the experimental nature of this treatment and its potential adverse effects, informed consent was obtained and the patient was given a new course of PE followed by 300 mg of natalizumab intravenously. We were anticipating to stabilize the clinical course of the disease and to prolong the time to the next PE required. However, she did not respond clinically to natalizumab and showed measurable disease progression on the Inflammatory Neuropathy Cause and Treatment scale6 3 weeks after the infusion, requiring a new course of PE. Our clinical observation was shown on magnetic resonance imaging (Figure 2), where strong gadolinium enhancement of the roots was visible prior to PE, reduced enhancement was visible after PE and prior to the infusion of natalizumab, and reappearance of strong gadolinium uptake of the roots was visible 3 weeks after natalizumab. The patient progressed clinically and currently requires weekly PE.

Place holder to copy figure label and caption
Figure 2.

Three T1-weighted magnetic resonance imaging scans of the lumbar spinal roots were sequentially performed. MRI I indicates magnetic resonance imaging prior to plasma exchange; MRI II, after plasma exchange, prior to natalizumab; MRI III, 3 weeks after natalizumab treatment. In all cases, gadolinium enhancement, indicating acute inflammation, was apparent along the roots (arrows) with a diminished signal after plasma exchange.

Graphic Jump Location

COMMENT

We describe a case of highly active CIDP that further deteriorated despite initiation of anti–α4 integrin therapy with natalizumab. By labeling natalizumab with biotin and applying this antibody for immunohistochemistry on a sural nerve biopsy from a patient with CIDP, we were able to stain the α4 integrin on perivascular T cells, which indicated that the target antigen of natalizumab is expressed in the peripheral nerve, underlining the rationale for our therapeutic attempt (Figure 3). Furthermore, we studied the saturation of the α4 integrin on peripheral venous T lymphocytes from our patient before and after treatment with natalizumab by flow cytometry analysis (Figure 4) as described before.7 This analysis revealed clear evidence that natalizumab sufficiently bound to its target antigen on T cells and as such could have been effective in blocking inflammatory egress out of the blood vessels into the peripheral nervous system.

Place holder to copy figure label and caption
Figure 3.

Sural nerve cross-section from a patient with chronic inflammatory demyelinating polyneuropathy. Staining with biotinylated natalizumab reveals expression of the α4 integrin on invading T cells (arrows). Green indicates anti-CD3-PE, phycoerythrin; red, natalizumab; and blue, 4,6-diamidino-2-phenylindol.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Ex vivo flow cytometry analysis detecting natalizumab bound to the cellular surface of T cells. Peripheral blood mononuclear cells were stained for CD3 and with an antihuman IgG to detect natalizumab as described before.5 A, In healthy controls only CD3 can be detected, whereas 3 weeks postinfusion, a strong signal for natalizumab can be obtained, which does not change after in vitro preincubation with natalizumab, indicating a nearly complete saturation of the target antigen. B, These levels appeared to be biologically relevant, as ex vivo isolated CD3+ T cells could not be loaded with additional natalizumab in vitro, indicative of a maximally effective natalizumab saturation after a single natalizumab infusion. Natalizumab was labeled with fluorescein isothiocyanate (Natmab-FITC). Binding of Natamab-FITC was completely abrogated in the presence of a 10-fold excess of unlabeled natalizumab (Natmab), which was used as a negative control. +Indicates added to the cells prior to fluorescent-activated cell sorter analysis.

Graphic Jump Location

The role of α4 integrin in the inflamed peripheral nerve is not fully understood. Experimental studies in an animal model suggest that blocking this molecule translates into clinical disease amelioration and induction of apoptosis in invading T lymphocytes within the peripheral nervous system.3 Our patient, however, did not show any clinical or paraclinical indications that natalizumab was effective. The antibody has a high affinity to its target antigen and already a single infusion translates into measurable efficacy, as seen on magnetic resonance imaging in patients with multiple sclerosis.8 Thus, despite the short treatment we could probably have expected some degree of effectiveness of the drug already after a single infusion. In addition, long-term therapy with natalizumab obviously exerts some long-lasting immunomodulatory changes that clearly exceed the immediate effects on transmigration over a short period.

Given the clinical and immunopathologic heterogeneity of CIDP, this case report clearly does not exclude natalizumab from being effective in patients with another subform of this immune-mediated disease. At present, however, given its safety profile,9 the application of natalizumab cannot be recommended in CIDP and should only be explored in controlled clinical trials.

ARTICLE INFORMATION

Correspondence: Bernd C. Kieseier, MD, Department of Neurology, Heinrich-Heine-University, Moorenstrasse 5, 40225 Düsseldorf, Germany (bernd.kieseier@uni-duesseldorf.de).

Accepted for Publication: September 22, 2009.

Author Contributions:Study concept and design: Menge, Meyer zu Hörste, and Kieseier. Acquisition of data: Wolf, Menge, Stenner, Saleh, Hartung, Wiendl, and Kieseier. Analysis and interpretation of data: Wolf, Menge, Stenner, Meyer zu Hörste, Saleh, Wiendl, and Kieseier. Drafting of the manuscript: Wolf, Menge, Stenner, Meyer zu Hörste, Wiendl, and Kieseier. Critical revision of the manuscript for important intellectual content: Menge, Stenner, Meyer zu Hörste, Saleh, Hartung, Wiendl, and Kieseier. Statistical analysis: Meyer zu Hörste. Obtained funding: Kieseier. Administrative, technical, and material support: Menge, Stenner, Meyer zu Hörste, Saleh, Wiendl, and Kieseier. Study supervision: Kieseier.

Financial Disclosure: Drs Hartung, Wiendl, and Kieseier have received honoraria for lecturing, travel expenses for attending meetings, and financial support for research from Bayer Health Care, Biogen Idec, Merck Serono, Novartis, Sanofi Aventis, and TEVA.

REFERENCES

Linker  RKieseier  BC Innovative monoclonal antibody therapies in multiple sclerosis. Ther Adv Neurol Disord 2008;1 (1) 33- 42
Link to Article
Enders  ULobb  RPepinsky  RBHartung  HPToyka  KVGold  R The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis in the Lewis rat. Brain 1998;121 (pt 7) 1257- 1266
PubMed Link to Article
Leussink  VIZettl  UKJander  S  et al.  Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol 2002;103 (2) 131- 136
PubMed Link to Article
Meyer zu Hörste  GHartung  HPKieseier  BC From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3 (4) 198- 211
PubMed Link to Article
Kieseier  BCWiendl  HHartung  HP The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006;19 (5) 433- 436
PubMed Link to Article
Hughes  RBensa  SWillison  H  et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50 (2) 195- 201
PubMed Link to Article
Stenner  MPWaschbisch  ABuck  D  et al.  Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One 2008;3 (10) e3319
PubMed Link to Article
Miller  DHKhan  OASheremata  WA  et al. International Natalizumab Multiple Sclerosis Trial Group, A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348 (1) 15- 23
PubMed Link to Article
Warnke  CMenge  THartung  HP  et al.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010;67 ((8).) In press

Figures

Place holder to copy figure label and caption
Figure 1.

Past therapeutic regimens of a patient with chronic inflammatory demyelinating polyneuropathy. IVIg indicates high-dose intravenous immunoglobulin; MRI I, magnetic resonance imaging prior to PE; MRI II, after PE, prior to natalizumab; MRI III, 3 weeks after natalizumab treatment; PE, plasma exchange.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Three T1-weighted magnetic resonance imaging scans of the lumbar spinal roots were sequentially performed. MRI I indicates magnetic resonance imaging prior to plasma exchange; MRI II, after plasma exchange, prior to natalizumab; MRI III, 3 weeks after natalizumab treatment. In all cases, gadolinium enhancement, indicating acute inflammation, was apparent along the roots (arrows) with a diminished signal after plasma exchange.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 3.

Sural nerve cross-section from a patient with chronic inflammatory demyelinating polyneuropathy. Staining with biotinylated natalizumab reveals expression of the α4 integrin on invading T cells (arrows). Green indicates anti-CD3-PE, phycoerythrin; red, natalizumab; and blue, 4,6-diamidino-2-phenylindol.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 4.

Ex vivo flow cytometry analysis detecting natalizumab bound to the cellular surface of T cells. Peripheral blood mononuclear cells were stained for CD3 and with an antihuman IgG to detect natalizumab as described before.5 A, In healthy controls only CD3 can be detected, whereas 3 weeks postinfusion, a strong signal for natalizumab can be obtained, which does not change after in vitro preincubation with natalizumab, indicating a nearly complete saturation of the target antigen. B, These levels appeared to be biologically relevant, as ex vivo isolated CD3+ T cells could not be loaded with additional natalizumab in vitro, indicative of a maximally effective natalizumab saturation after a single natalizumab infusion. Natalizumab was labeled with fluorescein isothiocyanate (Natmab-FITC). Binding of Natamab-FITC was completely abrogated in the presence of a 10-fold excess of unlabeled natalizumab (Natmab), which was used as a negative control. +Indicates added to the cells prior to fluorescent-activated cell sorter analysis.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Electrophysiological Assessments in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
Table Graphic Jump LocationTable 2.  Analysis of Cerebrospinal Fluid in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy

References

Linker  RKieseier  BC Innovative monoclonal antibody therapies in multiple sclerosis. Ther Adv Neurol Disord 2008;1 (1) 33- 42
Link to Article
Enders  ULobb  RPepinsky  RBHartung  HPToyka  KVGold  R The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis in the Lewis rat. Brain 1998;121 (pt 7) 1257- 1266
PubMed Link to Article
Leussink  VIZettl  UKJander  S  et al.  Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol 2002;103 (2) 131- 136
PubMed Link to Article
Meyer zu Hörste  GHartung  HPKieseier  BC From bench to bedside: experimental rationale for immune-specific therapies in the inflamed peripheral nerve. Nat Clin Pract Neurol 2007;3 (4) 198- 211
PubMed Link to Article
Kieseier  BCWiendl  HHartung  HP The inflamed peripheral nervous system: update on immune therapies. Curr Opin Neurol 2006;19 (5) 433- 436
PubMed Link to Article
Hughes  RBensa  SWillison  H  et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Group, Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50 (2) 195- 201
PubMed Link to Article
Stenner  MPWaschbisch  ABuck  D  et al.  Effects of natalizumab treatment on Foxp3+ T regulatory cells. PLoS One 2008;3 (10) e3319
PubMed Link to Article
Miller  DHKhan  OASheremata  WA  et al. International Natalizumab Multiple Sclerosis Trial Group, A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348 (1) 15- 23
PubMed Link to Article
Warnke  CMenge  THartung  HP  et al.  Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? Arch Neurol 2010;67 ((8).) In press

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,413 Views
21 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs